Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15433933 | 0.90 | HCRTR1 (0.33) | HCRTR1PIK3CASLC6A9MAPK1GPR142 | |
| SCHEMBL12980216 | 0.90 | PIK3CA (0.42) | PIK3CAGPR142CREBBP | |
| SCHEMBL9612759 | 0.89 | PIK3CA (0.43) | HCRTR1PIK3CAGPR142HPGD | |
| SCHEMBL9612478 | 0.85 | HCRTR1 (0.32) | HCRTR1SLC6A9 | |
| SCHEMBL9612558 | 0.83 | PIK3CA (0.37) | HCRTR1PIK3CAGPR142 | |
| SCHEMBL9612549 | 0.83 | ABL1 (0.39) | HCRTR1PIK3CAGPR142CREBBP | |
| SCHEMBL9612696 | 0.82 | GPR142 (0.34) | HCRTR1SLC6A9GPR142 | |
| SCHEMBL9612730 | 0.82 | KIF11 (0.31) | GPR142 | |
| SCHEMBL9612543 | 0.82 | PIK3CA (0.32) | PIK3CAGPR142 | |
| SCHEMBL9612431 | 0.82 | RAF1 (0.39) | PIK3CAMAPK1GPR142HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2012071509-A2 | BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | HCRTR1 1302/4885PIK3CA 3/4885SLC6A9 1502/4885 |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | HCRTR1 1302/4885PIK3CA 3/4885SLC6A9 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.